Nevertheless, rosiglitazone,a PPARγ agonist that can improve insulin sensitivity and glycemic control inpatients with type 2 diabetes, was found to increase PON1 activity, although therewas no significant change in the serum PON1 concentration (30). Here, INS is linked to type 2 diabetes mellitus.